{"id":24,"date":"2022-04-19T12:47:06","date_gmt":"2022-04-19T03:47:06","guid":{"rendered":"https:\/\/ccvd.kufm.kagoshima-u.ac.jp\/antiviral\/wpo\/?page_id=24"},"modified":"2022-05-23T14:42:47","modified_gmt":"2022-05-23T05:42:47","slug":"eng","status":"publish","type":"page","link":"https:\/\/ccvd.kufm.kagoshima-u.ac.jp\/antiviral\/eng\/","title":{"rendered":"English"},"content":{"rendered":"
\n
\n
\n
\n
\n
    \n
  1. <\/li>\n
  2. <\/li>\n<\/ol>\n
    \n
    \n

    \"image\"<\/p>\n

    \n

    DIVISION OF ANTIVIRAL THERAPY
    \nJOINT RESEARCH CENTER FOR
    \nHUMAN RETROVIRUS INFECTION
    \nNATIONAL KAGOSHIMA UNIVERSITY<\/h1>\n<\/div>\n<\/div>\n
    \n

    \"image\"<\/p>\n

    \n

    DIVISION OF ANTIVIRAL THERAPY
    \nJOINT RESEARCH CENTER FOR
    \nHUMAN RETROVIRUS INFECTION
    \nNATIONAL KAGOSHIMA UNIVERSITY<\/h1>\n<\/div>\n<\/div>\n<\/div>\n

    Previous<\/span><\/a>Next<\/span><\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

    \n
    \n
    \n
    \n
    \n
      \n
    1. <\/li>\n
    2. <\/li>\n<\/ol>\n
      \n
      \n

      \"image\"<\/p>\n

      \n

      DIVISION OF ANTIVIRAL THERAPY
      \nJOINT RESEARCH CENTER FOR
      \nHUMAN RETROVIRUS INFECTION
      \nNATIONAL KAGOSHIMA UNIVERSITY<\/h1>\n<\/div>\n<\/div>\n
      \n

      \"image\"<\/p>\n

      \n

      DIVISION OF ANTIVIRAL THERAPY
      \nJOINT RESEARCH CENTER FOR
      \nHUMAN RETROVIRUS INFECTION
      \nNATIONAL KAGOSHIMA UNIVERSITY<\/h1>\n<\/div>\n<\/div>\n<\/div>\n

      Previous<\/span><\/a>Next<\/span><\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

      \n
      \n
      \n
      \n
      \n
      \n

      \"image\"<\/a><\/p>\n

      DEVELOPMENT OF THERAPEUTIC AGENTS FOR HIV, HBV AND CYTOMEGALOVIRUS<\/h3>\n
      Related Article<\/a><\/div>\n<\/div>\n
      \n

      \"image\"<\/a><\/p>\n

      DEVELOPMENT OF NOVEL THERAPIES TO
      \nCURE HIV INFECTION<\/h2>\n
      Related Article<\/a><\/div>\n<\/div>\n
      \n

      \"image\"<\/a><\/p>\n

      STUDY ON THE IMMUNE RESPONSE AGAINST
      \nSARS-COV-2<\/h2>\n
      Related Article<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
      \n
      \n
      \n
      \n

      PUBLICATIONS<\/h2>\n

      MORE<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

      \n
      \n
      \n
      \n

      DEVELOPMENT OF ANTIRVIRAL DRUGS<\/h1>\n

      The history of the human immunodeficiency virus (HIV)\/AIDS therapy, which spans over 30 years, is one of the most dramatic stories of science and medicine leading to the treatment of a disease. Since the advent of the first AIDS drug, AZT or zidovudine, a number of agents acting on different drug targets, such as HIV enzymes (e.g. reverse transcriptase, protease, and integrase) and host cell factors critical for HIV infection (e.g. CD4 and CCR5), have been added to our armamentarium to combat HIV\/AIDS. The combination antiretroviral therapy (cART) using these anti-HIV drugs has been shown to potently suppress HIV-1 replication and successfully extend the life expectancy of HIV-1-infected individuals. However, we have encountered a number of problems in patients receiving cART, such as drug-related toxicities and HIV-1’s acquisition of resistance to existing antiretroviral regimens. Development of therapeutic agents for HBV (hepatitis B virus) and other viruses is also in progress. However, they also have problems in terms of activity and side effects. Hence, continuing efforts to develop newer antiviral agents is still essential.<\/p>\n

      Related Article 2<\/a><\/div>\n

      PURSUING HIV CURE<\/h1>\n

      The combination antiretroviral therapy (cART) has been shown to potently suppress HIV-1 replication and successfully extend the life expectancy of HIV-1-infected individuals. However, as one can recognize, it is thought that the combination therapy with existing antiretroviral agents does not eliminate\/eradicate latently HIV-1-infected cells (HIV-1 reservoir), and now we should start new challenges to utilize various drugs that have different mechanisms of action in order to pursue the possibility to achieve cure of HIV-1 infection and AIDS.<\/p>\n

      \n
      \n
      Related Article 2<\/a><\/div>\n<\/div>\n
      \n
      Related Article 3<\/a><\/div>\n<\/div>\n<\/div>\n

      THE COMBAT AGAINST COVID-19<\/h1>\n

      It goes without saying that the mRNA vaccine has been the trump card for the COVID-19 pandemic, but there is still no prospect of a pandemic convergence, and multiple treatment options, including orally available small molecule drugs, are needed.<\/p>\n

      \n
      \n
      Related Article 2<\/a><\/div>\n<\/div>\n
      \n
      Related Article 3<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
      \n
      \n
      \n
      \"KENJI<\/div>\n
      \n

      KENJI MAEDA, M.D., PH.D.<\/h3>\n

      Professor, Division of Antiviral Therapy<\/p>\n

      Personal History:
      \n<\/strong>1995\u3000Kumamoto University School of Medicine, Japan (M.D.)<\/p>\n

      2003\u3000Kumamoto University Graduate School of Medicine, Japan (Ph.D.)<\/p>\n

      2005-2015\u3000National Cancer Institute, National Institutes of Health, USA
      \n(Visiting Fellow & Staff Scientist)<\/p>\n

      2015-2022\u3000National Center for Global Health and Medicine (NCGM), Japan
      \nChief, Experimental Retrovirology Section
      \nDept. of Refractory Viral Infection, Research Institute<\/p>\n

      2022-\u3000Kagoshima University, Japan
      \nProfessor, Division of Antiviral Therapy
      \nJoint Research Center for Human Retrovirus Infection<\/p>\n

      ResearchGate<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n